Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nuvasive Inc (NUVA)

Nuvasive Inc (NUVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,947,169
  • Shares Outstanding, K 52,046
  • Annual Sales, $ 1,102 M
  • Annual Income, $ 12,480 K
  • 60-Month Beta 1.17
  • Price/Sales 3.49
  • Price/Cash Flow 14.25
  • Price/Book 4.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.63
  • Number of Estimates 8
  • High Estimate 0.66
  • Low Estimate 0.61
  • Prior Year 0.69
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.10 +8.19%
on 12/12/19
76.67 -1.08%
on 12/13/19
+3.41 (+4.71%)
since 11/13/19
3-Month
60.35 +25.67%
on 10/02/19
76.67 -1.08%
on 12/13/19
+10.89 (+16.77%)
since 09/13/19
52-Week
43.51 +74.30%
on 01/08/19
76.67 -1.08%
on 12/13/19
+19.69 (+35.07%)
since 12/13/18

Most Recent Stories

More News
Neogen's Food Safety Business Thrives on Ergot Alkaloids Test

The newly-developed Reveal Q+ MAX test is likely to fortify Neogen's (NEOG) presence in the global food allergen testing market.

NUVA : 75.84 (+2.69%)
RMD : 153.63 (+0.91%)
NEOG : 68.35 (-1.14%)
HAE : 116.49 (-0.58%)
Intersect ENT (XENT) Grows on Innovation Despite Cost Woes

The latest offering in Intersect ENT's (XENT) SINUVA portfolio is specific J code - J7401.

XENT : 21.52 (+0.19%)
NUVA : 75.84 (+2.69%)
RMD : 153.63 (+0.91%)
HAE : 116.49 (-0.58%)
Walgreens Extends Deal to Form GPO With Retail Giant Kroger

Per Walgreens (WBA), its alliance with Kroger will lead to supply chain efficiencies, capitalizing on their joint resources.

RMD : 153.63 (+0.91%)
HAE : 116.49 (-0.58%)
NUVA : 75.84 (+2.69%)
WBA : 57.88 (-1.19%)
Here's Why You Should Hold on to Quest Diagnostics Stock Now

Investors can retain Quest Diagnostics (DGX) stock in their portfolio, thanks to solid prospects.

HAE : 116.49 (-0.58%)
NUVA : 75.84 (+2.69%)
RMD : 153.63 (+0.91%)
DGX : 105.20 (-0.11%)
Here's Why You Should Add Omnicell to Your Portfolio Now

Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.

OMCL : 79.69 (-1.52%)
HAE : 116.49 (-0.58%)
RMD : 153.63 (+0.91%)
NUVA : 75.84 (+2.69%)
Omnicell (OMCL) Partners With Kit Check to Offer Bluesight

This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.

OMCL : 79.69 (-1.52%)
NUVA : 75.84 (+2.69%)
RMD : 153.63 (+0.91%)
HAE : 116.49 (-0.58%)
NUVA vs. HAE: Which Stock Should Value Investors Buy Now?

NUVA vs. HAE: Which Stock Is the Better Value Option?

NUVA : 75.84 (+2.69%)
HAE : 116.49 (-0.58%)
Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth

Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.

NUVA : 75.84 (+2.69%)
EW : 232.64 (+0.84%)
HAE : 116.49 (-0.58%)
RMD : 153.63 (+0.91%)
Amedisys (AMED) Benefits From Home Health and Personal Care

Amedisys' (AMED) impressive performance in the newly-unveiled Personal Care segment is appreciative.

RMD : 153.63 (+0.91%)
HAE : 116.49 (-0.58%)
NUVA : 75.84 (+2.69%)
AMED : 162.30 (-0.68%)
Thermo Fisher (TMO) at a 52-Week High: What's Driving It?

Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.

TMO : 320.50 (+0.36%)
HAE : 116.49 (-0.58%)
NUVA : 75.84 (+2.69%)
RMD : 153.63 (+0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NUVA with:

Business Summary

NuVasive, Inc. is transforming spine surgery and beyond with minimally invasive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, and software systems for surgical...

See More

Key Turning Points

2nd Resistance Point 77.75
1st Resistance Point 76.80
Last Price 75.84
1st Support Level 74.76
2nd Support Level 73.67

See More

52-Week High 76.67
Last Price 75.84
Fibonacci 61.8% 64.00
Fibonacci 50% 60.09
Fibonacci 38.2% 56.18
52-Week Low 43.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar